肝细胞癌降期至米兰标准内后肝移植的优异结局:一项多中心研究
这项回顾性多中心研究纳入2002至2012年加州3个肝移植中心187例连续接受统一降期方案的肝细胞癌成人患者,109例(58%)成功降期后接受肝移植,移植后1年生存率95%、5年生存率80%,无复发生存率分别为95%和87%,意向治疗分析未发现中心间差异。多因素分析显示治疗失败相关因素为治疗前甲胎蛋白>1000 ng/mL(风险比3.3,P<.001)和Child-Pugh B或C级(风险比1.6,P<.001)。
要点
- 统一降期方案后58%(109/187)患者成功降期并接受肝移植。
- 移植后1年生存率95%、5年生存率80%,无复发生存率分别为95%和87%。
- 治疗前甲胎蛋白>1000 ng/mL且Child-Pugh B或C级者2年治疗失败概率为100%。
核心结论
- 在统一方案的肝细胞癌降期回顾性多中心研究中,肝移植后结局优异且无中心特异性效应。
- 作者认为研究结果支持在更广泛范围应用该降期方案。
- Child-Pugh B或C级且甲胎蛋白>1000 ng/mL的患者不太可能从降期中获益。
研究设计与样本
- 回顾性多中心研究,纳入2002年至2012年加州3个肝移植中心(第5区)连续入组的187例接受降期方案的肝细胞癌成人患者。
- 所有患者每次局部区域治疗后1个月及至少每3个月接受腹部影像学检查。
- 主要结局为治疗失败概率,治疗失败定义为因肿瘤进展退出肝移植等待名单、未接受移植的肝病相关死亡或移植后肝细胞癌复发。
主要发现
- 109例(58%)成功降期后接受肝移植;仅1例移植标本为低分化,7例(6.4%)有血管侵犯。
- 基于移植后中位4.3年收集数据的Kaplan-Meier分析,1年生存率95%、5年生存率80%,无复发生存率分别为95%和87%。
- 意向治疗分析中中心间生存(P=.62)、肝移植后生存(P=.95)及肝细胞癌复发(P=.99)均无差异。
- 因肿瘤进展退出等待名单59例(32%),未接受肝移植的肝病相关死亡9例(5%)。
- 多因素分析中治疗失败相关因素为治疗前甲胎蛋白>1000 ng/mL(风险比3.3,P<.001)和Child-Pugh B或C级(风险比1.6,P<.001)。
临床怎么用
- 作者认为研究结果支持在更广泛范围应用该降期方案。
- 作者认为Child-Pugh B或C级且甲胎蛋白>1000 ng/mL的患者不太可能从降期中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Single-center studies have reported excellent outcomes of patients who underwent liver transplantation for hepatocellular carcinoma (HCC) after successful down-staging (reduction of tumor burden with local-regional therapy), but multi-center studies are lacking. We performed a multi-center study, applying a uniform down-staging protocol, to assess outcomes of liver transplantation and performed an intention to treat analysis. We analyzed factors associated with treatment failure, defined as dropout from the liver transplant waitlist due to tumor progression, liver-related death without transplant, or recurrence of HCC after transplant. METHODS: We performed a retrospective multi-center study of 187 consecutive adults with HCC enrolled in the down-staging protocol at 3 liver transplant centers in California (Region 5), from 2002 through 2012. All patients underwent abdominal imaging 1 month after each local-regional treatment, and at a minimum of once every 3 months. The primary outcome was probability of treatment failure. RESULTS: Liver transplantation was performed after successful down staging in 109 patients (58%). Tumor explant from only 1 patient had poorly differentiated grade and 7 (6.4%) had vascular invasion. Based on Kaplan-Meier analysis of data collected a median 4.3 years after liver transplantation, 95% of patients would survive 1 year and 80% of patients would survive 5 years; probabilities of recurrence-free survival were 95% and 87%, respectively. There were no center-specific differences in survival in the intention to treat analysis (P = .62), in survival after liver transplantation (P = .95), or in recurrence of HCC (P = .99). Patients were removed from the liver transplantation waitlist due to tumor progression in (n = 59; 32%) or liver-related death without liver transplantation (n = 9; 5%). Factors associated with treatment failure, based on multivariable analysis, were pre-treatment levels of alpha-fetoprotein (AFP) >1000 ng/mL (hazard ratio, 3.3; P < .001) and Child Pugh class B or C (hazard ratio, 1.6; P < .001). The probability of treatment failure at 2 years from the first down-staging procedure was 100% for patients with levels of AFP >1000 and Child Pugh class B or C vs 29.4% for patients with neither risk factor (P < .001). CONCLUSIONS: In a retrospective, multi-center study on HCC down staging under a uniform protocol, we found patients to have excellent outcomes following liver transplantation, with no center-specific effects. Our findings support application of the down-staging protocol on a broader scale. Patients with Child Pugh class B or C and AFP >1000 are unlikely to benefit from down staging.
引用
- Mehta N, Guy J, Frenette CT, et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2017. PMID: 29175528. doi:10.1016/j.cgh.2017.11.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。